South Korean biosimilars company Samsung Bioepis has sued Johnson & Johnson’s Janssen Biotech to invalidate two patents for Crohn’s disease drug Stelara, after reaching a licencing agreement over the medicine in the US.
Subscribe for instant access to all Lawyerly content.
